Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INPULSIS-2: Nintedanib in IPF
NCT01335477Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2011
- Primary completion
- Oct 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 17
01
Overview
A Phase 3 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started May 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01335477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335477.